PADCEV (enfortumab vedotin) Now Available in India for Locally Advanced or Metastatic Urothelial Cancer
Mumbai: Astellas Pharma India Pvt Ltd. today announced that PADCEVTM (
enfortumab vedotin
) is now available for prescription in India as monotherapy for the treatment of adult patients with locally advanced or
metastatic urothelial cancer
(LA/mUC) who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor1
Enfortumab vedotin is a first-in-class antibody-drug conjugate that is directed against
Nectin-4
, a protein located on the surface of cells and highly expressed in bladder cancer cells1Laboratory studies have shown that the anticancer activity occurs when it enters the cell and releases the cell-killing medicine that works to damage and kill the cell expressing nectin-4.1
In India, urothelial carcinoma patients who have progressed beyond platinum-containing chemotherapy and immunotherapy currently lack a standard of care. Treatment options for this population are limited and this launch will address a significant unmet need.
The launch of PADCEVTM
reinforces Astellas' commitment to expanding its oncology portfolio in India. Following the introduction of XospataTM (Gilteritinib) last April for relapsed or refractory FLT3+ acute myeloid leukemia (AML), PADCEVTM marks another step in the company's mission to deliver innovative cancer therapies to Indian patients.
'This launch marks a significant milestone for India. The approval of enfortumab vedotin provides a new treatment option for patients living with advanced urothelial cancer who have had limited treatment options thus far. It also further demonstrates our continued commitment to bringing global innovations to India and making a real impact on patient's lives,' said Sampada Gosavi, General Manager and Managing Director, Astellas India.
About Urothelial Cancer
Urothelial cancer is the most common type of bladder cancer (90 percent of cases) and can also be found in the renal pelvis (where urine collects inside the kidney), ureter (tube that connects the kidneys to the bladder) and urethra2.
About the EV-301 Trial
The EV-301 trial
(NCT03474107)
was a global, multicentre, open-label, randomised phase 3 trial designed to evaluate enfortumab vedotin versus physician's choice of chemotherapy (docetaxel, paclitaxel or vinflunine) in 608 patients with locally advanced or metastatic urothelial cancer who were previously treated with a PD-1/L1 inhibitor and platinum-containing therapies. The primary endpoint was overall survival and secondary endpoints included progression-free survival, overall response rate, duration of response and disease control rate, as well as assessment of safety/tolerability and quality-of-life parameters. Results were published in the
New England Journal of Medicine.
About PADCEV TM (enfortumab vedotin)
PADCEV is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer1,4. Nonclinical data suggest the anticancer activity of PADCEV is due to its binding to Nectin-4 expressing cells followed by the internalisation and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis).1
About Astellas
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.
For Further Information, Please Contact:
Astellas Pharma India Private Limited
301, 3rd Floor, C & B Square, 127, Andheri Kurla Road, Andheri (East), Mumbai 400069 India, Customer care no. +91-22-61557600
REFERENCES
1. PADCEV India Prescribing Information.
2. American Society of Clinical Oncology. Bladder cancer: introduction (5-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction. Accessed March 2022.
3. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021; 10.1056/NEJMoa2035807.
4. Challita-Eid P, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 2016;76(10):3003-13.
Disclaimer - The above content is non-editorial, and ET Healthworld hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
10 hours ago
- NDTV
1st Picture Of Dragon Spacecraft That Will Take Astronaut Shubhanshu Shukla To Space
The first picture of the Dragon spacecraft, set to carry Indian astronaut Shubhanshu Shukla on a historic mission to the International Space Station (ISS), have been made public. The spacecraft is built to transport four astronauts, who will return to Earth at the end of their mission. It has reached the hangar at pad 39A in Florida, where it is preparing for its first space flight. Astronauts from the United States, India, Poland, and Hungary will go on this thrilling adventure as part of a private mission by Axiom Space. SpaceX shared the first image of the rocket in a post on X and wrote, "Dragon arrives at the hangar at pad 39A in Florida ahead of its first flight. Falcon 9 is targeted to launch Dragon and @Axiom_Space's Ax-4 crew to the @Space_Station. Next Tuesday, June 10." Dragon arrives at the hangar at pad 39A in Florida ahead of its first flight. Falcon 9 is targeted to launch Dragon and @Axiom_Space 's Ax-4 crew to the @Space_Station next Tuesday, June 10 — SpaceX (@SpaceX) June 5, 2025 The earlier liftoff was scheduled for June 8, 2025, at 6.41 pm but was postponed by two days to June 10. While no reason was officially announced for the delay, a source said it happened to "account for the weather during vehicle transportation and completing final processing of the vehicle ahead of launch". Group Captain Shukla is scheduled to pilot the Axiom-4 mission, a private astronaut mission that will launch aboard a SpaceX Dragon capsule on a SpaceX Falcon 9 rocket. In a statement, Axiom Space said, "The launch of the Axiom-4 crew will take place from Launch Complex 39A at NASA's Kennedy Space Centre in Florida". His space voyage is a historic one for India, coming forty years after Rakesh Sharma's iconic spaceflight on Russia's Soyuz spacecraft in 1984. It is particularly significant as it will help India's space travel program and the Gaganyaan mission. Slawosz Uznanski-Wisniewski from Poland, Tibor Kapu from Hungary, and Peggy Whitson, a former NASA astronaut and mission commander, will accompany Group Captain Shukla on this space trip. The astronauts will perform scientific, outreach and commercial activities on board the orbiting laboratory for up to 14 days after docking.
The Hindu
12 hours ago
- The Hindu
Mango prices fall sharply, farmers demand compensation
As mango farmers in Madurai district face a roadblock in selling their produce to traders due to the abysmally low prices fixed by them, they are demanding compensation or a solution for procurement of fruits at a better price. Though the farmers witnessed lower yields in the last few years, this year farmers enjoyed a good harvest, but they could not reap the benefits, said Jeeva, a farmer from Kesampatti near Melur. He added that the good cultivation could have benefitted them if a fixed and regularised procurement system was in practice. 'I have about 100 trees in three acres of land, and the cultivation was about 25 tonne this year,' he stated. But, the traders, who went to procure the produce wanted them for just Rs.4 per kg, he added. When the procurement price was about Rs.25 per kg last year, this year, the drastic drop in the price has put the farmers in a tight spot, Mr. Jeeva said. 'We hear that as big corporate which procure the kizhimooku variety of mangoes for juices and other products does want to procure them this year, the traders refuse to procure them at good price,' he stated. Opposing the dependence on corporates, he said that when the entire market was dependent on corporate companies, they would be the one to fix prices and manipulate them based on their needs. The Tamil Nadu Farmers Association has urged the Tamil Nadu government to immediately fix a Minimum Support Price (MSP) for mangoes to ensure that growers were not exploited by market forces. Further, they have also demanded compensation for farmers who have suffered losses due to the price crash. Madurai district agricultural officials cited the over production of mangoes as reason for the price crash. As the climate for the growth of mangoes was conducive, the farmers witnessed a good yield, but that has in turn reduced the demand for the fruit, the official stated. However, their demands for compensation and fixation of MSP would all be discussed with the government for further action, the official added.
NDTV
14 hours ago
- NDTV
Axiom-4 Spaceflight Mission Commander's Message For PM Modi
Quick Read Summary is AI generated, newsroom reviewed. Dr Peggy Whitson emphasizes to PM Modi the importance of merging commercial and government space programme for India's future in space. She supports Group Captain Shubhanshu Shukla's upcoming Axiom Mission 4 flight to the ISS. New Delhi: The director of human spaceflight at Axiom Dr Peggy A Whitson has a message for Prime Minister Narendra Modi - the integration of commercial and government space programmes is the future. Former NASA astronaut Dr Whitson and Indian Air Force (IAF) Group Captain Shubhanshu Shukla, who is set to become the second Indian to go to space, spoke about their planned private spaceflight to the International Space Station under the Axiom Mission 4 in partnership with Elon Musk's SpaceX and NASA. To a question by NDTV on PM Modi's plan for sending an Indian to the Moon by 2047 and whether Group Captain Shukla would be laying the first steps for India's Gaganyaan, Dr Whitson said, "Well, I really do believe we are helping India's space programme by having somebody like Shubhanshu get this experience. I think it will be something that he can tie in and build into the future." "I think for the Prime Minister, it's important to really get the word out about this mission and the future of the Indian space programme. It's important for him to encourage industry and technology as a result of this to try and expand even more on the capabilities, because as I said before, the integration of commercial and government space is going to be where the future leads us," Dr Whitson, one of the most experienced astronauts in the world, told NDTV. The Axiom mission to the ISS has been postponed to June 10. The astronauts are set to be launched into space on board SpaceX's Falcon-9 rocket from Kennedy Space Centre in Florida, the same launchpad from where the Apollo 11 mission to the Moon blasted off. The spaceflight was originally scheduled for May 29 and then rescheduled to June 8. The Axiom-4 crew also comprises mission specialists Slawosz Uznanski-Wisniewski from Poland and Tibor Kapu from Hungary, taking the total crew to four. Group Captain Shukla will be the second Indian to travel to space, four decades after Rakesh Sharma's iconic spaceflight onboard Russia's Soyuz spacecraft in 1984. PM Modi is expected to interact with the Axiom-4 crew during their 14-day stay at the ISS.
